ICU Medical reported a challenging fourth quarter with declining revenues and a net loss, primarily driven by a significant drop in the Vital Care segment. Despite a slight improvement in gross margin, the company's adjusted EBITDA and adjusted EPS also saw a year-over-year decrease, reflecting ongoing operational headwinds.
GAAP gross margin improved to 38% from 36% in the prior year's fourth quarter.
positiveConsumables revenue increased 6% year-over-year to $284.7 million.
positiveInfusion Systems revenue increased 3% year-over-year to $176.3 million.
positiveFree cash flow for the twelve months ended December 31, 2025 was $99.9 million.
positiveTotal revenues decreased 14% year-over-year to $540.7 million in Q4 FY2025.
negativeVital Care product line revenue plummeted 58% year-over-year to $79.7 million in Q4 FY2025, significantly impacting overall revenue.
negativeGAAP net loss for Q4 FY2025 was $(15.7) million, or $(0.64) per diluted share, compared to a net loss of $(23.8) million, or $(0.97) per diluted share, in Q4 FY2024.
negativeAdjusted diluted EPS decreased to $1.91 in Q4 FY2025 from $2.11 in Q4 FY2024.
negativeAdjusted EBITDA decreased to $98.2 million in Q4 FY2025 from $105.5 million in Q4 FY2024.
negativeInventories increased to $615.9 million from $584.7 million year-over-year.
attentionMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
| Segment | Current | Prior Yr | YoY | % Total |
|---|---|---|---|---|
Consumables | N/A | — | — | — |
Infusion Systems | N/A | — | — | — |
Vital Care | N/A | — | — | — |
| Total Revenue | $0.00M | — | — | 100.0% |
Segment performance shows business unit health and growth drivers.
Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.
Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.
Fourth quarter results were generally in line with our expectations.
Focus on providing quality, innovation and value to our clinical customers worldwide.
The Company will host a conference call to discuss its fourth quarter and full year 2025 financial results.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.